A lot of your questions will need to wait for the full paper being published as I don’t want to steal the thunder of Nikki’s team so I will avoid commenting on questions 1 to 3.
In regards 4 the independent conditions have been measured, but not all yet.
In answer to question 5, twice a week worked better than once a week. In humans, bisantrene is likely to be used twice in a week once every 4 weeks on a constant background of oral decitabine. The aim is to balance toxicity with anticancer efficacy. Ultimately, the exact protocol used will be up to the investigator.
A lot of your questions will need to wait for the full paper...
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.56 |
Change
0.010(0.65%) |
Mkt cap ! $265.8M | |||
| Open | High | Low | Value | Volume |
| $1.55 | $1.56 | $1.51 | $95.69K | 62.25K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3015 | $1.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.56 | 4018 | 1 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |